Tag: CA125

Continuous bevacizumab plus second line chemotherapy beyond progression during or after maintenance bevacizumab

http://dx.doi.org/10.18081/jcc/016-06/12-23 Journal of Cellular Cancer  Volume 8, Issue 1, pages 12-23 Received January 28, 2016; accepted May 21, 2016; published June 17, 2016 Haider Y. Shukur1* Abstract Bevacizumab has FDA approval in the first and second line treatment combined with chemotherapy of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who […]